298. Hereditary pancreatitis Clinical trials / Disease details
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02713997 (ClinicalTrials.gov) | December 2016 | 29/2/2016 | Anti-inflammatory Therapy to Improve Outcomes After TPIAT | Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet Autotransplantation | Pancreatitis, Chronic; Diabetes; Transplant | Drug: etanercept;Drug: Alpha 1-Antitrypsin | University of Minnesota | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 18 Years | 65 Years | All | 45 | Phase 4 | United States |